dismiss

Mark your calendars: the next Clean Sweep Live Auction will be on Thursday, January 25th--Click to view the full catalogue

DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

 

More Industry Headlines

Donald Trump had a CT scan, here's what we learned President deemed healthy despite presence of heart disease

Bupa and HealthTap build personalized health records with AI Enhances quality, speed and convenience of care available

3D Systems and Stryker to enhance personalized surgical planning together Develop virtual surgical planning and anatomical models

Lower costs and rapid care for cardiology patients tied to eConsults May save payors more than $400 per patient

Burnout, depression continue to plague U.S. physicians New report highlights the growing burden of bureaucratic tasks on provider health

Cloud-based medical imaging informatics market to reach $830.5 million by 2021 Driven by need for cost-effective and flexible solutions

Allegheny Health Network first in Penn. to use Synaptive's robotic surgery system Specifically for cranial and spinal procedures

Hit with $6.2 billion charge, GE considering major shake-ups CEO Flannery 'deeply disappointed' and weighing all options

Ultrasound-based technology may be able to treat cancer Can it replace radiotherapy one day?

RaySearch to supply TPS for Japanese carbon ion therapy facility First RayStation carbon ion installation in Japan

IBA spins off radiopharmaceutical division

by Brendon Nafziger , DOTmed News Associate Editor
New York private equity firm SK Capital Partners bought a controlling stake in Ion Beam Applications S.A.'s radiopharmaceutical division, which is being spun off into its own company, IBA announced Monday. Under the terms of the new deal, SK Capital will own 60 percent of the new business, called IBA Molecular Imaging, and IBA will retain a 40 percent stake.

The transaction, expected to close in the second quarter, is valued at 180 million euros ($229 million). IBA said it expects to net 100 million euros ($127 million) from the deal after debt adjustments, although the sale will result in "significant exceptional loss" for 2011 accounts as the transaction "does not value the IBA radiopharmaceutical business at the level previously booked in its consolidated statements," the company said in a statement.

Story Continues Below Advertisement

Industry Leading Wireless DR Systems from RadmediX

Acuity 14×17 is a completly wireless, cassette sized X-Ray detector. It can easily transform any conventional x-ray room into Digital in just minutes with no special tools required. Get a Quote Today!



IBA's stock shot up to a six-month high after the announcement, Reuters reports, rising more than 31 percent and hitting 6.31 euros per share in trading Monday.

Although IBA owns 40 percent of the new company, it will reap 60 percent of the profits for drugs currently under development, in recognition of its past R&D investments, the Belgian company said. In the pipeline are imaging tracers to help diagnose kidney disease and Alzheimer's disease. The development costs of the in-the-works drugs now would be shared equally, the companies said.

Renaud Dehareng, the radiopharmaceutical group's former president, will helm the new entity as CEO, IBA said.

IBA's molecular imaging group employs 1,000 people, has 57 nuclear medicine sites in Europe, the United States and Asia, and runs a manufacturing facility in France. It generates about 175 million euros ($222 million) in yearly revenues, IBA said.

In a separate announcement, IBA said Olivier Legrain, the current chief strategic officer, would be promoted to chief operating officer in preparation for when he takes the reins from CEO Pierre Mottet, who's stepping down in May. However, Mottet will continue with the company as vice-chairman of the board.

IBA, which also makes cyclotrons for proton therapy treatments, is headquartered in Louvain-la-Neuve, Belgium.

Related:


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.
ALL RIGHTS RESERVED